# Community Health Systems Inc: financial statements, quarterly

CYH · NYSE · CIK 1108109 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyh.md) · [Financials](/companies/cyh/financials.md) · [Filings](/companies/cyh/filings.md) · [Insiders](/companies/cyh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cyh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,182 d](/filings/0001193125-26-059509.md) | [3,140](/filings/0000950170-25-058115.md) | [3,140](/filings/0000950170-25-098357.md) | [3,090](/filings/0001193125-25-250030.md) | [3,265 d](/filings/0001193125-26-059509.md) | [3,159](/filings/0001193125-26-170557.md) | [3,133](/filings/0001193125-26-314196.md) | [3,087](/filings/0001193125-26-437869.md) | [3,106 d](/filings/0001193125-26-059509.md) | [2,965](/filings/0001193125-26-170557.md) | [2,825](/filings/0001193125-26-314196.md) | [2,757](/filings/0001193125-26-437869.md) |
| Cost of revenue | $m | [494 d](/filings/0001193125-26-059509.md) | [487](/filings/0000950170-25-058115.md) | [483](/filings/0000950170-25-098357.md) | [469](/filings/0001193125-25-250030.md) | [507 d](/filings/0001193125-26-059509.md) | [489](/filings/0001193125-26-170557.md) | [469](/filings/0001193125-26-314196.md) | [460](/filings/0001193125-26-437869.md) | [446 d](/filings/0001193125-26-059509.md) | [441](/filings/0001193125-26-170557.md) | [401](/filings/0001193125-26-314196.md) | [407](/filings/0001193125-26-437869.md) |
| Operating income | $m | [327 d](/filings/0001193125-26-059509.md) | [231](/filings/0000950170-25-058115.md) | [238](/filings/0000950170-25-098357.md) | [(205)](/filings/0001193125-25-250030.md) | [278 d](/filings/0001193125-26-059509.md) | [284](/filings/0001193125-26-170557.md) | [512](/filings/0001193125-26-314196.md) | [243](/filings/0001193125-26-437869.md) | [450 d](/filings/0001193125-26-059509.md) | [281](/filings/0001193125-26-170557.md) | [389](/filings/0001193125-26-314196.md) | [146](/filings/0001193125-26-437869.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [107 d](/filings/0001193125-26-059509.md) | [28.0](/filings/0000950170-25-058115.md) | [24.0](/filings/0000950170-25-098357.md) | [(64.0)](/filings/0001193125-25-250030.md) | [92.0 d](/filings/0001193125-26-059509.md) | [42.0](/filings/0001193125-26-170557.md) | [118](/filings/0001193125-26-314196.md) | [(173)](/filings/0001193125-26-437869.md) | [61.0 d](/filings/0001193125-26-059509.md) | [89.0](/filings/0001193125-26-170557.md) | [76.0](/filings/0001193125-26-314196.md) | [(3.0)](/filings/0001193125-26-437869.md) |
| Net income | $m | [47.0 d](/filings/0001193125-26-059509.md) | [(41.0)](/filings/0000950170-25-058115.md) | [(13.0)](/filings/0000950170-25-098357.md) | [(391)](/filings/0001193125-25-250030.md) | [(70.0) d](/filings/0001193125-26-059509.md) | [(13.0)](/filings/0001193125-26-170557.md) | [282](/filings/0001193125-26-314196.md) | [130](/filings/0001193125-26-437869.md) | [110 d](/filings/0001193125-26-059509.md) | [(58.0)](/filings/0001193125-26-170557.md) | [70.0](/filings/0001193125-26-314196.md) | [(86.0)](/filings/0001193125-26-437869.md) |
| Diluted EPS | $ per share | not reported | [(0.32)](/filings/0000950170-25-058115.md) | [(0.10)](/filings/0000950170-25-098357.md) | [(2.95)](/filings/0001193125-25-250030.md) | not reported | [(0.10)](/filings/0001193125-26-170557.md) | [2.09](/filings/0001193125-26-314196.md) | [0.96](/filings/0001193125-26-437869.md) | not reported | [(0.43)](/filings/0001193125-26-170557.md) | [0.51](/filings/0001193125-26-314196.md) | [(0.63)](/filings/0001193125-26-437869.md) |
| Basic EPS | $ per share | not reported | [(0.32)](/filings/0000950170-25-058115.md) | [(0.10)](/filings/0000950170-25-098357.md) | [(2.95)](/filings/0001193125-25-250030.md) | not reported | [(0.10)](/filings/0001193125-26-170557.md) | [2.11](/filings/0001193125-26-314196.md) | [0.97](/filings/0001193125-26-437869.md) | not reported | [(0.43)](/filings/0001193125-26-170557.md) | [0.51](/filings/0001193125-26-314196.md) | [(0.63)](/filings/0001193125-26-437869.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.0](/filings/0000950170-25-023242.md) | [0.0](/filings/0000950170-24-048396.md) | [0.0](/filings/0000950170-24-086552.md) | [0.0](/filings/0000950170-24-117088.md) | [0.0](/filings/0001193125-26-059509.md) | [0.4](/filings/0000950170-25-058115.md) | [0.5](/filings/0000950170-25-098357.md) | [0.1](/filings/0001193125-25-250030.md) | [0.3](/filings/0001193125-26-437869.md) | [0.7](/filings/0001193125-26-170557.md) | [0.1](/filings/0001193125-26-314196.md) | [0.2](/filings/0001193125-26-437869.md) |
| Current assets | $bn | [3.2](/filings/0000950170-25-023242.md) | [3.2](/filings/0000950170-24-048396.md) | [3.2](/filings/0000950170-24-086552.md) | [3.1](/filings/0000950170-24-117088.md) | [3.3](/filings/0001193125-26-059509.md) | [3.4](/filings/0000950170-25-058115.md) | [3.7](/filings/0000950170-25-098357.md) | [3.2](/filings/0001193125-25-250030.md) | [3.2](/filings/0001193125-26-437869.md) | [3.8](/filings/0001193125-26-170557.md) | [3.1](/filings/0001193125-26-314196.md) | [3.0](/filings/0001193125-26-437869.md) |
| Total assets | $bn | [14.5](/filings/0000950170-25-023242.md) | [14.4](/filings/0000950170-24-048396.md) | [14.4](/filings/0000950170-24-086552.md) | [13.9](/filings/0000950170-24-117088.md) | [14.1](/filings/0001193125-26-059509.md) | [13.9](/filings/0000950170-25-058115.md) | [13.6](/filings/0000950170-25-098357.md) | [13.2](/filings/0001193125-25-250030.md) | [13.2](/filings/0001193125-26-437869.md) | [13.2](/filings/0001193125-26-170557.md) | [12.2](/filings/0001193125-26-314196.md) | [12.1](/filings/0001193125-26-437869.md) |
| Current liabilities | $bn | [2.1](/filings/0000950170-25-023242.md) | [2.1](/filings/0000950170-24-048396.md) | [2.2](/filings/0000950170-24-086552.md) | [2.1](/filings/0000950170-24-117088.md) | [2.3](/filings/0001193125-26-059509.md) | [2.4](/filings/0000950170-25-058115.md) | [2.3](/filings/0000950170-25-098357.md) | [2.2](/filings/0001193125-25-250030.md) | [2.2](/filings/0001193125-26-437869.md) | [2.6](/filings/0001193125-26-170557.md) | [2.0](/filings/0001193125-26-314196.md) | [2.0](/filings/0001193125-26-437869.md) |
| Total liabilities | $bn | [15.3](/filings/0000950170-25-023242.md) | [15.3](/filings/0000950170-24-048396.md) | [15.3](/filings/0000950170-24-086552.md) | [15.2](/filings/0000950170-24-117088.md) | [15.4](/filings/0001193125-26-059509.md) | [15.2](/filings/0000950170-25-058115.md) | [14.7](/filings/0000950170-25-098357.md) | [14.2](/filings/0001193125-25-250030.md) | [14.0](/filings/0001193125-26-437869.md) | [14.1](/filings/0001193125-26-170557.md) | [13.0](/filings/0001193125-26-314196.md) | [13.0](/filings/0001193125-26-437869.md) |
| Long-term debt | $bn | [11.5](/filings/0000950170-25-023242.md) | [11.5](/filings/0000950170-24-048396.md) | [11.5](/filings/0000950170-24-086552.md) | [11.5](/filings/0000950170-24-117088.md) | [11.4](/filings/0001193125-26-059509.md) | [11.3](/filings/0000950170-25-058115.md) | [10.8](/filings/0000950170-25-098357.md) | [10.6](/filings/0001193125-25-250030.md) | [10.4](/filings/0001193125-26-437869.md) | [10.1](/filings/0001193125-26-170557.md) | [9.6](/filings/0001193125-26-314196.md) | [9.6](/filings/0001193125-26-437869.md) |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [(1.4)](/filings/0000950170-25-023242.md) | [(1.4)](/filings/0000950170-24-048396.md) | [(1.4)](/filings/0000950170-24-086552.md) | [(1.8)](/filings/0000950170-24-117088.md) | [(1.9)](/filings/0001193125-26-059509.md) | [(1.9)](/filings/0000950170-25-058115.md) | [(1.6)](/filings/0000950170-25-098357.md) | [(1.5)](/filings/0001193125-25-250030.md) | [(1.4)](/filings/0001193125-26-437869.md) | [(1.5)](/filings/0001193125-26-170557.md) | [(1.4)](/filings/0001193125-26-314196.md) | [(1.5)](/filings/0001193125-26-437869.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [90.0 d](/filings/0001193125-26-059509.md) | [96.0](/filings/0000950170-25-058115.md) | [101 d](/filings/0000950170-25-098357.md) | [67.0 d](/filings/0001193125-25-250030.md) | [216 d](/filings/0001193125-26-059509.md) | [120](/filings/0001193125-26-170557.md) | [88.0 d](/filings/0001193125-26-314196.md) | [69.0 d](/filings/0001193125-26-437869.md) | [266 d](/filings/0001193125-26-059509.md) | [(297)](/filings/0001193125-26-170557.md) | [88.0 d](/filings/0001193125-26-314196.md) | [154 d](/filings/0001193125-26-437869.md) |
| Capital expenditure | $m | [110 d](/filings/0001193125-26-059509.md) | [93.0](/filings/0000950170-25-058115.md) | [88.0 d](/filings/0000950170-25-098357.md) | [70.0 d](/filings/0001193125-25-250030.md) | [109 d](/filings/0001193125-26-059509.md) | [85.0](/filings/0001193125-26-170557.md) | [91.0 d](/filings/0001193125-26-314196.md) | [65.0 d](/filings/0001193125-26-437869.md) | [94.0 d](/filings/0001193125-26-059509.md) | [76.0](/filings/0001193125-26-170557.md) | [76.0 d](/filings/0001193125-26-314196.md) | [87.0 d](/filings/0001193125-26-437869.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [130](/filings/0000950170-24-048396.md) | [131](/filings/0000950170-24-086552.md) | [131](/filings/0000950170-24-117088.md) | [131](/filings/0000950170-25-058115.md) | [132](/filings/0000950170-25-098357.md) | [132](/filings/0001193125-25-250030.md) | [133](/filings/0001193125-26-170557.md) | [135](/filings/0001193125-26-314196.md) | [135](/filings/0001193125-26-437869.md) | [134](/filings/0001193125-26-170557.md) | [137](/filings/0001193125-26-314196.md) | [136](/filings/0001193125-26-437869.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 141,026,656 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-437869.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:46 ET. No prices; not investment advice.